The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1473909
ID1 and ID3 functions in the modulation of the tumour immune microenvironment in Adult Patients with B-Cell Acute Lymphoblastic Leukaemia
Provisionally accepted- 1 National Cancer Institute (Colombia), Bogotá, Colombia
- 2 National University of Colombia, Bogotá, Bogota, Colombia
- 3 San Ignacio University Hospital, Bogotá, Cundinamarca, Colombia
- 4 Versiti Blood Research Institute, Milwaukee, Wisconsin, United States
- 5 Foundation University of Health Sciences, Bogotá, Cundinamarca, Colombia
- 6 Pontifical Javeriana University, Bogotá, Cundinamarca, Colombia
- 7 LSU Health Sciences Center New Orleans, Louisiana State University, New Orleans, Louisiana, United States
The diagnosis of B-Cell acute lymphoblastic leukaemia (B-ALL) in adults often carries a poor prognosis. ID1 and ID3 genes have been identified as predictors of poor response in Colombian adult B-ALL patients, playing roles in cancer development. In different cancer models, these genes have been associated with immune regulator populations within the tumour immune microenvironment (TIME). B-ALL development alters the immune cell composition and the bone marrow (BM) tumour microenvironment, affecting disease progression and response to therapy. This study analyses gene expression levels of ID1 and ID3 in relation to TIME and immune evasion. This exploratory study analysed BM samples from 10 B-ALL adult patients diagnosed at the National Cancer Institute of Colombia. First, RT-qPCR was used to assess ID1 and ID3 expression in BM tumor cells. Flow cytometry characterized immune populations in the TIME. RNA-seq evaluated immune genes associated with B-ALL immune response, while xCell and CytoSig analyzed TIME cell profiles and cytokines. Pathway analysis, gene ontology, and differential gene expression (DEGs) were examined, with functional enrichment analysis performed using KEGG ontology. Patients were divided into two groups based on ID1 and ID3 expression, namely basal and overexpression. A total of 94 differentially expressed genes were identified between these groups, with top overexpressed genes associated with neutrophil pathways. Gene set enrichment analysis revealed increased expression of genes associated with neutrophil degranulation, immune response-related neutrophil activation, and neutrophilmediated immunity. These findings correlated with xCell data. Overexpression group showed significant differences in neutrophils (p=0.0008), monocytes (<0.0001) and CD4+ naive T cells (p=0.0240) compared to basal group patients. Microenvironment and immune scores were also significantly different (p=0.0016 and p=0.0017, respectively), consistent with the flow cytometry results. Elevated cytokine levels associated with neutrophil activation supported these findings. Validation was performed using the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) TCGA B-ALL cohorts. Our results show important differences between the expression level of ID1 and ID3 in cancer cells and the populations of TIME, suggesting a role in evading the immune response of ID1 and ID3 in B-ALL, mainly related to neutrophil pathways.
Keywords: B-Cell acute lymphoblastic leukaemia (B-ALL) 1, Immune Evasion 2, Immune system 3, Microenvironment 4, Bone marrow 5, Immunosurveillance 6
Received: 31 Jul 2024; Accepted: 07 Nov 2024.
Copyright: © 2024 Poveda-Garavito, Orozco, Torres-Llanos, Cruz-Rodriguez, Parra-Medina, Quijano, Zabaleta and Combita. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Nathaly Poveda-Garavito, National Cancer Institute (Colombia), Bogotá, Colombia
Alba Lucia Combita, National Cancer Institute (Colombia), Bogotá, Colombia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.